Abstract: The present invention provides protein markers present in a person's blood sample (such as a plasma, serum, or whole blood sample) that are associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

Abstract: The therapeutic uses of febuxostat or febuxostat derivatives and compositions comprising febuxostat or febuxostat derivatives to promote neurogenesis for the treatment of disease.

Abstract: The present invention provides genetic markers associated with the Alzheimer's Disease (AD), diagnostic and treatment methods for AD, and kits for diagnosing AD.

Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Abstract: Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.

Abstract: The therapeutic uses of febuxostat or febuxostat derivatives and compositions comprising febuxostat or febuxostat derivatives to promote neurogenesis for the treatment of disease.

Abstract: Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.

Abstract: The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vectors are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.

Abstract: Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.

Abstract: Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving ?-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

Abstract: Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving ?-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases caused or exacerbated by overactivated EphA4 signaling are provided. Also provided are methods for identifying additional compounds as therapeutic agents useful for treating conditions involving overly active EphA4 signaling.

Abstract: This invention relates to extracts and refined fractions of a traditional Chinese medicinal herb, Alpinia officinarum (AO), components thereof, and the use of such compounds and compositions to treat neurodegenerative or neuropathological conditions or to inhibit aggregation of a-synuclein.

Abstract: Methods and cosmetic compositions for conditioning the skin, utilizing as active ingredients selected compounds structurally related to astragenols, cycloastragenols, and/or protopanaxatriols, are provided. Such compounds include those of formulas (I), (II) and (III) described herein.

Abstract: Isolated compounds from Adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the Adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.

Abstract: The invention provides Stat3 and Tyk2 targets that have importance for diagnosis of neurodegenerative diseases such as Alzheimer's disease. Stat3 and Tyk2 are also important as targets for drug development for neurodegenerative diseases.

Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.

Abstract: Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.

Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.

Abstract: Provided are water and alcohol extracts of Rhizoma arisaematis, compounds isolated from Rhizoma arisaematis (such as 3-O-(9,12-octadecadienoyl)-glyceryl-?-D-galactopyranoside, N-(?-D-ribofuranos-1-yl)-phenylalanine, and adenosine), pharmaceutical compositions comprising the aforementioned ingredients, as well as uses thereof for promoting wound healing. In one embodiment, the pharmaceutical composition is a topical formulation, such as a cream, ointment, foam, lotion, plaster, gel, and emulsion.